Nitazoxanide, an Antiprotozoal Drug, Reduces Bone Loss in Ovariectomized Mice by Inhibition of RANKL-Induced Osteoclastogenesis

Nitazoxanide (NTZ) is an FDA-approved anti-parasitic drug with broad-spectrum anti-infective, anti-inflammatory, and antineoplastic potential. However, its regulatory effects on osteoclastogenesis and the underlying mechanisms remain unclear. The present study found that NTZ potently inhibited osteo...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Chang-hong, Lü, Zi-rui, Zhao, Zhen-da, Wang, Xin-yu, Leng, Hui-jie, Niu, Yan, Wang, Mo-pei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8696474/
https://www.ncbi.nlm.nih.gov/pubmed/34955850
http://dx.doi.org/10.3389/fphar.2021.781640

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8696474/
https://www.ncbi.nlm.nih.gov/pubmed/34955850
http://dx.doi.org/10.3389/fphar.2021.781640

Ejemplares similares